Ameresco (AMRC) Q1 2026 Earnings Transcript

Ameresco reported Q1 revenue up 14% year over year, with project revenue up 16% to $291 million, O&M revenue up 22%, and awarded backlog up 20% to $2.8 billion. The company also announced a $400 million HASI joint venture for Neogenix Fuels, implying a roughly $1.8 billion enterprise value and providing $300 million of growth capital plus $100 million to Ameresco. Guidance was reaffirmed on revenue, with Q2 adjusted EBITDA expected at $58 million-$62 million and non-GAAP EPS of $0.18-$0.23, though weather disruptions pressured gross margin and the company remained unprofitable in the quarter.

Analysis

AMRC’s most important development is not the quarter itself; it is the monetization of a capital-intensive, high-growth asset into a partially de-risked platform with external funding. That changes the company’s economic profile from “grow-or-bust” to a more capital-efficient compounder, and it should narrow the valuation discount vs. peers if the market trusts the disclosure treatment of the JV and noncontrolling interest. The second-order effect is that incremental corporate cash can now be redirected into higher-ROIC project origination, which is where AMRC can actually earn its cost of capital instead of endlessly funding long-dated biogas builds.

The near-term earnings setup is better than the headline loss suggests. The backlog math and the company’s ability to pull revenue forward imply decent visibility into the next two quarters, while weather is a transient headwind rather than a demand issue. The bigger risk is execution slippage in the second half: if project conversion slows or RNG output remains volatile, the market will re-focus on negative GAAP earnings and leverage optics, especially because the equity story still depends on clean classification of nonrecourse structures and steady tax equity markets.

The contrarian point is that the market may be underestimating how much optionality AMRC just created. A 70/30 funded JV that can lever assets and use tax-credit monetization means a relatively small amount of parent capital can support a much larger buildout over the next 2-4 years, which should raise the implied growth rate of the biofuels platform without requiring balance-sheet strain. On the other hand, the valuation reset may be less immediate than bulls expect if investors discount the 2028+ permitting timeline and treat the new JV as a long-duration asset with execution risk rather than an instant multiple re-rate.

Key Decisions for Investors

• Go long AMRC on a 3-6 month horizon; use post-event weakness to build a starter position. Risk/reward improves if the market begins capitalizing the JV monetization and cash reallocation, with upside to a re-rate if leverage optics stay contained.
• Pair trade: long AMRC / short a higher-quality but slower-growth infrastructure/services peer basket over 6-12 months. Thesis: AMRC has more valuation convexity from asset monetization and backlog conversion, while peers lack a similar funding catalyst.
• Buy AMRC call spreads 6-9 months out rather than outright stock if you want asymmetric exposure to a multiple expansion. The trade works if the market accepts the JV as de-risking and ignores the near-term GAAP loss noise.
• Avoid chasing HASI after the headline, but keep it as a secondary long if the market prices in the JV financing as a recurring origination channel. The cleaner trade is AMRC, where the funding benefit is more accretive to corporate flexibility.
• If AMRC rallies hard on the next print, consider trimming into strength unless second-half project conversion and RNG uptime improve simultaneously; the main downside is a fade back toward a sum-of-the-parts skepticism if execution data disappoints.